Company intelligence / Profile preview

i-medicus

Conshohocken, PA, United Statesmedicuspharma.com ↗

Ownership: Private
Development stage: Other

Overview

The lead asset, SkinJect’s D-MNA patch containing doxorubicin, is in Phase II clinical trials for basal cell carcinoma. Trials are ongoing in the US and UAE with patient recruitment underway at multiple sites. No topline results have been published as of June 2025.

Therapeutic areas: Oncology
Modalities: Drug device combination productSmall molecule (doxorubicin)Microneedle array technology
Industry: Biotech

Partnerships

Potential partnerships under discussion to complete clinical development and commercialization; no major pharma partners disclosed as of June 2025.

Beyond the preview

Go deeper on i-medicus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on i-medicus.

Explore the full profile